Orient Bio

Orient Bio Debt Growth

The Year-over-Year Debt Growth of Orient Bio (002630.KS) as of Oct 21, 2026 is -8.76 %. In the previous year, Year-over-Year Debt Growth was 12.32 % — a change of -171.07% (lower).

Debt Growth

-8.76 %

YoY

-171.07%

Last updated:

Year-over-Year Debt Growth of Orient Bio is 2022 -8.76 % . Year-over-Year Debt Growth of Orient Bio was 2021 12.32 % . It decreases by -171.07% lower compared to the previous year.

The Orient Bio Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2015
3.77 KRW
Jan 1, 2016
-0.12 KRW
Jan 1, 2017
-11.66 KRW
Jan 1, 2018
24.08 KRW
Jan 1, 2019
-87.14 KRW
Jan 1, 2020
-12.51 KRW
Jan 1, 2021
12.32 KRW
Jan 1, 2022
-8.76 KRW
The Orient Bio Debt Growth history
YEARDebt GrowthYoY
-8.76 %-171.07%
12.32 %-198.55%
-12.51 %-85.65%
-87.14 %-461.88%
24.08 %-306.58%
-11.66 %+9,427.15%
-0.12 %-103.25%
3.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Year-over-Year Debt Growth of Orient Bio is -8.76 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Orient Bio

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Orient Bio